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The term Cerebral Amyloid Angiopathy (CAA) is used to describe the pathological changes occurring in cerebral blood vessels, both
leptomeningeal and cortical that result from the deposition of amyloid proteins. This CNS vasculopathy is associated with a spectrum of
clinical phenotypes that include both ischemic and hemorrhagic presentations. Dementia, cognitive impairment and transient neurological
symptoms or signs are also being increasingly recognized as part of the CAA clinical spectrum.
This review covers the clinical, pathological and neuroimaging aspects of CAA.
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Cerebral Amyloid Angiopathy is defined by the deposi-
tion of amyloid proteins within leptomeningeal and cortical
arteries, arterioles, capillaries, and rarely veins. The term
amyloid refers to any amorphous, eosinophilic, extracellular
protein deposit with specific staining characteristics, such as
Congo red binding and birefringence with polarized light
(Fig. 1) [1,2]. There are a number of different proteins that
can deposit as amyloid in human CAA (Table 1).
In sporadic and most of the hereditary forms of CAA the
amyloid includes β-amyloid peptides 1–40 and 1–42 which
aggregate within vessel walls, occasionally spreading and
depositing in the surrounding neuropil or within the glia
limitans when capillaries are involved (Fig. 2) [1–3]. The
composition of the vascular amyloid deposits differs from
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doi:10.1016/j.jns.2007.01.054increased Aβ 40/42 ratio, which seems to shift the amyloid
deposition from the parenchyma to the vascular wall [4,5].
CAA occurs within a heterogeneous group of hereditary
and sporadic diseases. Hereditary forms account for the
minority of the CAA cases but have more pleomorphic
phenotypes (Table 1). Sporadic CAA increases dramatically
with age, rarely being present before the age of 50, and
increasing in prevalence to more than 50% in people over
age 90 [3,6]. Data from autopsy series have confirmed age as
being a significant risk factor in a variety of different
populations [7–9]. Though CAA is frequently presumed to
be asymptomatic, it is now increasingly recognized to
present with a spectrum of clinical presentations.
2. Historical overview
The histological vascular abnormalities recognizable as
vascular amyloid deposition were first described by Gustav
Oppenheim, in the brain parenchyma adjacent to hyalinized
capillary walls in 6 of 14 autopsied brains of individuals with
dementia and the pathology of AD [10]. In 1938, Scholz
published the first article in which the primary focus was the
Fig. 1. CAA in sporadic case of Alzheimer's Disease. (A) Congo-red
positive material in vessel wall, (B) confirmed as amyloid by showing apple-
green birefringence when viewed with polarized light.
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this abnormality in the brains of 15 of 104 unselected autop-
sies, and he suggested it to be a disease related to aging [10].
Although it has been nearly a century since the first
pathological descriptions of CAA, knowledge of its link
with intracerebral hemorrhage was recognized only in 1960,
when Neumann [11] reported on a 45-year old woman with
severe Cerebral Amyloid Angiopathy who had 2 symptomatic
lobar hemorrhages and multiple small asymptomatic lobar
petechial hemorrhages (PH). After this description further
interest followed when it was appreciated that there was CAA
underlying a significant proportion of cerebral hemorrhages
occurring in non-hypertensive individuals [11,12]. Following
these seminal descriptions, there has been an emerging
clinical and neuroimaging interest in both sporadic and
hereditary cases in the correlations with this pathology.
3. The clinical spectrum of sporadic CAA
The different clinical presentations that are recognized to
be associated with CAA may be divided syndromically into
stroke; transient neurological events including TIAs, sei-
zures, and migrainous phenomena; cognitive impairment
and dementia [1,3].
3.1. Stroke
3.1.1. Lobar cerebral hemorrhage
The most recognized clinical presentation of CAA and the
basis for the clinical criteria set by the Boston group [13,14],
is lobar cerebral hemorrhage which is frequently recurrent
[2,3,15]. Indeed, the antemortem diagnosis of CAA is most
often established around this presentation [13,15,16]. CAA-
related lobar hemorrhages usually affect normotensive
individuals over age 55. They account for 5–20% of all
spontaneous (non-traumatic) cerebral hemorrhages in elderly
subjects [17,18]. The CAA lobar hematoma typically
involves the cortical–subcortical regions and can extend
from the cortex to the subarachnoid space or less commonly,
to the ventricles. Recurrent and multiple hemorrhages are a
feature of CAA-related lobar hemorrhage in patients who
survive the initial bleed [1,3]. The localization of CAA-
related hemorrhage follows the localization of CAA in
the cerebral cortex and cortico–subcortical or lobar regions
[1–3,15]. Despite the high prevalence of CAA in the
occipital cortex, CAA-related hemorrhages have been shown
to be more evenly distributed [1,3], with a slight predom-
inance of occipital and frontal cortices [15]. Patients present
with cortical dysfunction that correlates to the extent and
location of lesions, typically preceded or coincident with a
headache, vomiting and nuchal rigidity [19]. CAA is
typically absent in regions characteristic of hypertensive
hemorrhages (deep brain regions and cerebellum) (Fig. 3).
The presence of petechial hemorrhages in a cortical/
subcortical location detected by low signal on gradient-
recalled-echo (GRE) MRI sequences with T2⁎-weightingfurther supports the diagnosis of CAA (Fig. 2) [13]. This low
signal is caused by deposited iron products (Fig. 4) [20]. These
small cortical–subcortical petechial hemorrhages correlate
well with the pathological diagnosis of CAA [13,20]. From the
diagnostic standpoint gradient echo MRI has emerged as the
most important diagnostic aid for CAA identification during
life. The lack of other accurate and accessible biomarkers has
otherwise limited knowledge of early detection, characteriza-
tion of the different clinical presentations of CAA and the
potential impact on the patients' neurological status.
Fibrinoid necrosis and aneurysm formation are both
implicated in the in the pathogenesis of vessel rupture [1–3].
Possession of the apoE ε2 and 4 alleles has been associated
with both fibrinoid necrosis and concentric splitting (“double-
barrel” appearance) of the blood-vesselwalls (Fig. 5) [21]. It is,
therefore, not unexpected that patients with CAA-related
hemorrhages and the 2/4 genotype (i.e, with both “risk” alleles)
have early and recurrent lobar hemorrhages [21–23]. Never-
theless, at present apoE genotyping does not have a recom-
mended place in the clinical setting for this problem.
There is an emerging question regarding the risks of
hemorrhagic complications of thrombolytic agents (e.g.
tissue plasminogen activator — rtPA) in patients with
CAA. Thrombolysis-related intracerebral hemorrhage in
patients with myocardial infarction has similar risk factors
and the hematoma features as sporadic CAA related hem-
orrhages [24]. On the other hand, in a small series of patients
Table 1
Genetic, clinical, radiological and pathological data from hereditary forms of CAA
Hereditary CAA Gene/
mutation
Amyloid
Protein
Age of
onset
Clinical Phenotype Neuroradiological
phenotype
Pathological phenotype
Hereditary cerebral
hemorrhage with
amyloidosis-Dutch type
[30,54–58]
APP
E693Q
mutation
Aβ 39–76 Lobar brain hemorrhages;
dementia in survivors;
epilepsy in survivors.
Lobar hemorrhages;
PHs in the gray-white
matter junction in
T2⁎MRI; infarcts;
diffuse white matter
damage.
CAA affects cerebral and
cerebellar meningeal arteries
and cerebro-cortical arterioles.
CAA is more severe occipitally;
Diffuse plaques; Hemorrhages
and infarcts.
Hereditary CAA -
Iowa type
[31,59]
APP
D694N
mutation
Aβ 60–70 Progressive aphasia/
dementia; Lobar brain
hemorrhage (in Spanish
kindred).
Occipital gyriform
calcification and l
eukoencephalopathy.
Extensive CAA; Calcified
deposits in vessel walls; Diffuse
plaques; NFTs; Cortical infarcts
and hemorrhages.Cortical PHs in
T2⁎MRI.
Hereditary CAA -
Flemish type
[60–62]
APP
A692G
mutation
Aβ 41–61 Amnesic syndrome/
dementia; Lobar brain
hemorrhage.
Cortical central
atrophy; white matter
lesions; Lobar brain
hemorrhages.
Extensive CAA large amyloid
core SP cerebral and cerebellar
and NFTs.
Hereditary CAA -
Italian kindred
[63,64]
APP
E693K
mutation
Aβ 50s Lobar brain hemorrhages. NA Extensive CAA.
Hereditary cerebral
hemorrhage with
amyloidosis-
Icelandic type
[2,65]
CystC
Leu68Gln
Acys 20–50 Lobar brain hemorrhages;
cognitive impairment or
dementia in survivors.
NA Extensive CAA within small
arteries and arterioles of
leptomeninges, cerebral cortex,
basal ganglia, brainstem, and
cerebellum.
Familial amyloid
polyneuropathy/
meningo-
vascular
amyloidoses
[66–71]
TTR
Asp18Gly
or
Val30Gly
or Tyr69His
ATTR 36–53 Dementia, ataxia, and
spasticity. Dementia, seizures,
ataxia, hemiparesis, and
decreased vision.
Subarachnoid hemorrhage.
Symmetric
calcification of the
cortex; MRI contrast
enhancement at the
surface of the cortex.
TTR-amyloid deposits
predominated in cerebrospinal
leptomeningeal vessels and in
subpial and subependymal
regions. Brain parenchyma is
not involved.Superficial siderosis.
Familial
amyloidoses
Finnish type [72]
GEL
G654A or
G654T
AGel 30 Dementia, ataxia,
neuropsychiatric features;
corneal lattice dystrophy, cranial
and peripheral neuropathy
White matter lesions
in postmortem MRI.
Minor cortical CAA,
white matter AGel angiopathy
and myelin loss; major spinal
angiopathy.
Prion disease with
cerebral amyloid
angiopathy [73]
PRNP
Y145Stop
APrP 38 Dementia, extrapyramidal
signs, ataxia and spastic
paraparesis.
Late cerebral atrophy
and ventricular
dilatation.
Extensive CAA in
leptomeningeal and
parenchymal vessels, NFTs in
cortex. Severe gliosis and
neuronal loss.
Familial British
dementia [2,53]
BRI2 ABRi 40–60 Dementia; spasticity;
ataxia; rare Lobar brain
hemorrhages.
Frontal and occipital
white matter lesions;
lesion in the corpus
callosum. No
evidence of
hemorrhages.
Extensive CAA affecting
vessels in the leptomeninges
and both gray and white matter;
abundant amyloid plaques
and severe neurofibrillary
degeneration.
Mutation in
stop codon
Familial Danish
dementia [74,75]
BRI2
decamer
duplication
in codon
265–266
ADan 30 Cataracts; deafness; dementia;
spasticity; ataxia; rare strokes.
White matter lesions. Extensive CAA in cerebral
vessels, choroid plexus,
cerebellum, spinal cord,
and retina; plaques and
neurofibrillary tangles;
ischemic lesions in white matter.
Uniform diffuse atrophy .
Familial
Alzheimer's
Disease and
Down Syndrome [76–81]
PS1 PS2;
APP
Aβ Variable Dementia; Lobar brain
hemorrhages and spastic
paraparesis
Variable Variable CAA.
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imaging was reported to not substantially increase the risk of
either symptomatic or asymptomatic brain hemorrhagefollowing IV rtPA administered between 3 and 6 h after
stroke onset [25]. More prospective data is required in order
to clarify the risk of hemorrhagic complications with the use
Fig. 2. Sporadic case of Alzheimer's Disease. A-beta Immunohistochemistry
demonstrating A-beta protein deposition in the walls of leptomeningeal and
parenchymal vessels (CAA) and in senile plaques.
Fig. 4. Axial T2⁎GRE MR with T2⁎-weighting image of sporadic CAA
case. Multiple petechial cortical hemorrhages (black arrowheads) and a
major lobar brain hemorrhage (white arrowhead).
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recommendations to guide antithrombotic or fibrinolytic
treatment based on the detection of cerebral petechial
hemorrhages on MRI [24,26].
3.1.2. Ischemic infarctions
Manifestations of cerebral ischemia should be considered
within the clinical spectrum of CAA. CAA related ischemic
infarcts are more often located in the cerebral cortex, with
lesions that have been described as ‘cortical lacunes’. These
cortically based lesions may present as TIAs or minor
strokes in elderly CAA patients [12,27]. CAAwith ischemic
infarctions are observed in patients, with both hereditary
and, less frequently, sporadic forms of CAA [12,28–31].
In tissue biopsies of patients with a history of recent
cerebral or cerebellar infarctions, CAA was found in 13%
of cases, compared to 3.7% of controls, OR 3.8 (95%
confidence-interval 1.3–10.9) [32].Fig. 3. CT scan of a biopsy proven CAA patient that presented with a stroke
syndrome. Acute left frontal lobe hemorrhage. Peri-ventricular white matter
hyperdensity.The pathogenic mechanisms underlying ischemic lesions
related to CAA remains uncertain. Whether it is through
vascular stenosis or obstruction, or whether it results from a
dynamic change in the vessel physiology or both, is
presently debated [33,34].
3.1.3. Subarachnoid hemorrhage (SAH)
Over age 60, CAA is a rare cause of primary SAH yet it is
the most frequent cause of ICH accompanying secondary
SAH [35]. The SAH source may be intraparenchymal with
hemorrhage extending into the subarachnoid space or from
leptomeningeal vessels leaking into the subarachnoid space.
Further studies are still needed to clarify this issue [36].
There have been descriptions of localized SAH or
superficial siderosis over cortical sulci in patients that
presented with transient neurological symptoms, in patientsFig. 5. Double barrel appearance of CAA of an amyloid-laden vessel in a
case of sporadic CAA.
Fig. 6. CT Scan of a probable CAA patient that presented with left sensitive
seizures and post-ictal left hemiparesis, showing a right perirolandic
subarachnoid hemorrhage.
Fig. 7. Axial T2⁎GREMR image of autopsy proven sporadic CAA case that
experimented transient neurological symptoms (aphasia and right motor
deficit). This image shows low signal in a gyriform pattern over the left
parietal lobe, attributable to deposited iron products in a superficial
meningeal or subpial location.
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extensive involvement of the meningo-cortical vessels by the
amyloid deposits and its rupture underlies the SAH and related
clinical manifestations that can be recognized in CAA.
3.2. Transient focal neurological symptoms and signs (TFNSS)
TFNSS can include different phenomena such as focal
seizures with or without Todd's paralysis, focal deficits
(TIAs) or positive visual symptoms similar to migrainous
auras. Most of the published cases describe brief stereotypic
phenomena that sometimes preceded major hemorrhagic
events. A favorable response to antiepileptic drugs supports
an epileptic mechanism for some TFNSS [38].
There have been no systematic studies elucidating these
phenomena in patients with CAAwith only case reports in the
literature [27,37,38]. The transitory nature of the clinical
symptoms and signs, coupled with the absence of a clear
CAA biomarker make clinical–pathological correlation
difficult to establish. Underlying the TFNSS different
pathologies have been described including: petechial cortical
hemorrhages [38], subpial–subarachnoid hemorrhages [37]
or ischemic lesions (“cortical lacunes”) (Figs. 4, 6 and 7) [27].
3.3. Cognitive impairment and dementia
The relationship of CAA with cognitive impairment and
dementia has been well recognized. There is an inverse
correlation between CAA presence and cognitive function
that has been reported in both case series [39] as well as in
the population based studies. In the MRC study, severe CAA
was identified in 36.5% of individuals with dementia com-
pared to 7% without dementia, OR 7.7 (95% CI, 3.3 to 20.4)
[7]. CAA is present in N80% of AD case-series [8,17]. In the
Honolulu-Asia Aging Study (HAAS), the comorbid pres-
ence of CAA with AD was associated with significantlyworse cognitive test performance [40]. CAA can cause both
mild cognitive impairment and full blown dementia, in
sporadic and hereditary cases [41].
CAA impairs cognitive function through a number of dif-
ferentmechanisms that include: 1.— Ischemic or hemorrhagic
lesions which disrupt neuronal circuits or cause strategic
lesions [42]; 2. — Interference with cerebrovascular auto-
regulation in response to blood pressure with resultant ische-
mia to white matter supplied by Aβ-laden meningocortical
arteries [43]; 3. — Lowering the threshold of dementia in a
predisposed patient (e.g. AD patient) [40,44] either by
neuronal loss associated with the severity of CAA [45] or by
functional disturbance of the transport of essential nutrients
across the blood–brain barrier as a result of the deposition of
Aβ in capillaries [44]. The observed patterns of cognitive
impairment are related to the underlying mechanisms and
location of vascular injury inCAA. Stepwise decline can occur
both with recurrent lobar hemorrhage as well as with recurrent
ischemia [1–3]. Though CAA related hemorrhages are known
to involve cortical–subcortical regions and spare the structures
most usually associated with strategic infarcts (e.g. thalamus
and caudate), affected cortical regions (e.g. right parietal) can
be, solely responsible for the cognitive decline of patients with
CAA [46]. As well, the severity of white matter disease
(WMD) and the presence of silent infarction on MRI scan are
identified as important risk factors for subsequent cognitive
decline and development of dementia [47].
Several studies support the hypothesis that there are links
between white matter damage and CAA. There is diffuse
white matter damage in hereditary forms of CAA (e.g. Dutch
and Iowa) while in sporadic CAA there is often periventricular
28 L.F. Maia et al. / Journal of the Neurological Sciences 257 (2007) 23–30leukoencephalopathy featuring gliosis, myelin loss, and
hyalinization of the blood vessel walls [30,48]. White matter
disease is associated with increased cognitive decline in about
20% of the patients, particularly those where it is severe.
Patients with WMD have a high incidence of concomitant
petechial hemorrhages that can negatively affect their cog-
nitive performance [39]. Though not specifically addressed, it
is presumed that the involvement of the subcortical and
particularly periventricular white matter, and the concomitant
circuit disruption leads to a pattern of cognitive decline where
apathy, impaired executive function and psychomotor slowing
predominating over impaired episodic memory. On the other
hand, when the memory deficit is the dominant presenting
feature, over speed of processing, gait and other cognitive
domains it is plausible that both parenchymal and vascular
amyloid are playing synergistic roles in the process.
3.4. Subacute to rapidly progressive cognitive decline
There are some clinical circumstances, where CAA
becomes associated with a more rapidly progressive rate of
cognitive decline and dementia. In such instances the Aβ
vascular deposits or CAA seem to become associated with a
full blown angiitis, where there is a profuse inflammatory
response including multinucleated giant cells in vessel walls
and where macrophages can be seen to have internalized
amyloid [49,50]. There have been a total of 41 cases with
such a CAA associated angiitis wherein a rapidly progressive
dementia has been the most frequent presentation. Language
and praxis are amongst the most frequently affected
cognitive domains within these cases while headaches,
seizures, hallucinations and confusion have also been
reported concomitantly. These case series are likely biased
towards the most serious presentations that progressed to
autopsy, leaving open to speculation whether there might be
more minor clinical symptoms might be seen in CAA
patients with lesser inflammatory responses.
The aggressive clinical and radiographic picture observed
in these patients, and the responses to immunosuppressive
treatment has suggested that the inflammation is playing a
direct role.
In isolated case-reports CAA has been described with a
reversible leukoencephalopathy, sometimes associated with
documented vessel inflammation, and other times with hyper-
tension though these are not frequent presentations [51,52].
3.5. Hereditary forms of CAA
Hereditary forms of CAA are rare and account for a
minority of the CAA cases. [2] Most of these forms of CAA
are associated with amyloid precursor protein mutations
while they also occur with mutations of cystatin C, presenilin,
prion protein, transthyretin, gelsolin and in other amyloidoses
[30,31,53–80]. There is some recognized phenotypic vari-
ability where the clinical characteristics within the hereditary
group include a broader spectrum of presentations thanwithin sporadic disease, usually with a younger age of onset
(Table 1). Clinical signs in the hereditary forms can include
spastic paraparesis, extrapyramidal signs, progressive ataxia
or ocular disturbances, features that have not been part of the
spectrum of sporadic cases [66–75].
These already characterized families (Table 1) demon-
strate the pleomorphism of CAA clinical presentations and
the need for further characterization of sporadic CAA to
elaborate whether these are systematic differences between
the hereditary and sporadic forms.
3.6. Aging and CAA
CAA is a frequent finding in autopsy series of individuals
without dementia (3–50%), particularly over the age of 65. It
is not clear if in this context CAA is part of the normal aging
process [3,7,18] or whether individuals were completely
asymptomatic as these relationships are most often addressed
retrospectively. The majority of these individuals have mild
or moderate CAA, with symptoms and signs that may be
very subtle or remain unnoticed by clinicians [2,3].
4. Conclusion
CAA describes pathological changes that occur in cerebral
blood vessels, both leptomeningeal and cortical resulting
from the deposition of amyloid proteins. The spectrum of
clinical manifestations of CAA is evolving with recognition
of hemorrhagic complications that range from subtle side-
rosis to large lobar hemorrhages. CAA has important
relationships with cerebral white matter disease, subarach-
noid hemorrhage and intraparenchymal lesions. Vascular
function may be impeded in a variety of ways in CAAwhich
allows for a broad clinical spectrum to be appreciated. In rare
instances it may act as a trigger to a more aggressive dementia
and inflammatory vasculopathy. Intracerebral hemorrhage in
a cortical–subcortical location remains the most reliable
method for diagnosing CAA during life aided through the use
of gradient echo MRI.
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